Standard Biotools (LAB) Amortization of Deferred Charges (2017 - 2023)

Standard Biotools (LAB) has reported Amortization of Deferred Charges for 7 consecutive years, with $173000.0 the latest figure, recorded in Q4 2023.

• On a quarterly basis, Amortization of Deferred Charges fell 14.36% year-over-year to $173000.0 in Q4 2023; TTM through Dec 2023 was $770000.0, a 7.23% decrease from a year earlier, with the FY2023 full-year figure at $770000.0, down 7.23% from the prior year.
• Amortization of Deferred Charges was $173000.0 for Q4 2023 at Standard Biotools, down from $187000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $2.0 million in Q1 2019 and troughed at -$194000.0 in Q4 2019.
• A 5-year average of $269500.0 and a median of $194500.0 in 2022 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges tumbled 107.28% in 2019 and soared 205.0% in 2021, its largest moves.
• Over 5 years, Amortization of Deferred Charges stood at -$194000.0 in 2019, then soared by 167.01% to $130000.0 in 2020, then surged by 228.46% to $427000.0 in 2021, then slumped by 52.69% to $202000.0 in 2022, then retreated by 14.36% to $173000.0 in 2023.
• The last three Amortization of Deferred Charges figures came in at $173000.0 (Q4 2023), $187000.0 (Q3 2023), and $206000.0 (Q2 2023), per Business Quant data.